Min.Order / FOB Price:Get Latest Price
1 Gram |
FOB Price:USD 0.0200 -0.0300 |
GMP manufacturer Afatinib Afatinib Lower Price Afatinib
Product name: | Afatinib (BIBW 2992);Gilotrif |
Synonyms: | BIBW 2992;N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide;Tovok;Tovok, BIBW 2992;BIBW2992 Afatinib;Afatinib (BIBW 2992);ToMtovok;(S,E)-N-(4-(3-chloro-4-fluorophenylaMino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(diMethylaMino)but-2-enaMide |
CAS: | 439081-18-2 |
MF: | C24H25ClFN5O3 |
MW: | 485.944 |
Purity: | 99.5% min |
Appearance: | White or Nearly White Crystalline Powder |
MOQ: | 10G |
Specifications: | Pharmaceutical Grade |
Deliver time: | About 5 days |
Deliver methods: | TNT,EMS,HKEMS,DHL,ect.(door to door) |
Afatinib is pronounced aff-a-tin-ib. It has the brand name Giotrif (jee-oh-triff). It is a type of biological therapy called a tyrosine kinase inhibitor (TKI). It is a treatment for non small cell lung cancer that has spread outside the lung or to other parts of the body.
It has received regulatory approval for use as a treatment for non-small cell lung cancer,although there is emerging evidence to support its use in other cancers such as breast cancer.
3. How afatinib works:
This type of drug works by blocking particular proteins on cancer cells that encourage the cancer to grow. Afatinib blocks proteins called epidermal receptors (EGFR). Cancers that have these receptors are called EGFR positive.
Between 10 and 15 people out of every 100 with non small cell lung cancer (10 to 15%) have EGFR positive cancer. Doctors check your cancer cells to see if they have the receptors before you have this treatment.
Afatinib may shrink the cancer or stop it growing for a time
4. Uses and fuction:
Afatinib is used to treat a certain type of lung cancer (non-small cell lung cancer) that has spread to other parts of the body. It belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal receptor-EGFR) in some tumors.
5. Mechanism of action:
Like lapatinib and neratinib, afatinib is a protein kinase inhibitor that also irreversibly inhibits human epidermal receptor 2 (Her2) and epidermal receptor (EGFR) kinases. Afatinib is not only active against EGFR mutations targeted by first generation tyrosine-kinase inhibitors (TKIs) likeerlotinib or gefitinib, but also against mutations such as T790M which are not sensitive to these standard therapies.Because of its additional activity against Her2, it is being investigated for breast cancer as well as other EGFR and Her2 driven cancers.
To facilitate tracheal intubation, mechanical ventilation, and surgical access, NMB agents are frequently used as non-anesthetic adjuncts in surgical procedures. Sugammadex is able to function as a pharmacologic sink of rocuronium and vecuronium, another non-depolarizing neuromuscular blocker, without the cardiovascular adverse effects experienced with reversal agents that directly interact with the cholinergic system. The γ-cyclodextrin has been designed to enhance binding of the guest by incorporating acidic side chains to promote an electrostatic interaction with the positive nitrogen of the blocker. Starting with γ-cyclodextrin, these side chains are readily installed by first halogenating with iodine or bromines to provide a handle for nucleophilic displacement with either 3-mercaptopropionic acid in the presence of sodium hydrides or with 3-mercaptopropionic acid methyl ester and cesium carbonate. The latter requires hydrolysis with sodium hydroxides to generate sugammadex sodium.
Chemical PropertiesColorless, orthorhombic crystals from DMF + water. d 1.446. Solubility in water.
UsesReversal agent for neuromuscular blocking drugs.
Afatinib is a drug approved for the treatment non-small cell lung carcinoma(NSCLC), developed by Boehringer Ingelheim.
It acts as a angiokinase inhibitor.
Like lapatinib and neratinib, afatinib is a tyrosine kinase inhibitor (TKI) that also irreversibly inhibits human epidermal
receptor (EGFR) kinases. Afatinib is not only active against
EGFR mutations targeted by first generation TKIs likeerlotinib or gefitinib, but also against those not sensitive to these
standard therapies. Because of its additional activity against Her2, it is being investigated for breast cancer as well as
other EGFR and Her2 driven cancers.
1. We has 11 years' exporting experience in pharmaceutical ingredient products.
Our professional and thoughtful after-sales service eliminates your worries.
2.We can provide you with ten thousands of products of different levels.
3. We offer convenient one-station purchasing service.
(1)Any inquiries will be replied within 12 hours.
(2)Dedication to quality, supply & service.
(3)Strictly on selecting raw materials.
(4)Reasonable & competitive price, fast lead time.
Wuhan Kanal Technology Co., Ltd. founded in 2010,it is a large manufacturer of fine Pharmaceutical& Chemical & Cosmetic materials that integrates R&D, production and sales together. Our Kanal company is established under the support of the Wuhan city government, so Kanal has large advantages in enterprise credit, finance security, product quality control, and cargo export.Kanal locates in the national new materials industry park of Wuhan city and is awarded the title of high-tech corporation.
Wuhan Kanal has its own R&D and development laboratory. We Kanal set up a R&D team with rich experience and strong technical strength, most of the practitioners have more than ten years' experience and technology in organic synthesis development. It owns almost 15 acre and more than 280 workers.
An ISO 9001 & GMP qualified company, we are mainly specialized in producing high quality but low price Pharmaceutical intermediates, APIs and other fine chemicals & cosmetics products which related to human and animals medicines as well as additives in gas &oil field, almost half of the goods are for exporting. What's more, we provide the OEM (customize) manufactures, if you can't find materials from the world, then tell us, we will research and produce in our high-tech equipmented laboratory. We are dedicated to satisfying our customers with our products and services.
1. We has 11 years' exporting experience in active pharmaceutical ingredient products.
Our professional and thoughtful after-sales service eliminates your worries.
2.We can provide you with ten thousands of products of different levels.
3. We offer convenient one-station purchasing service.
(1)Any inquiries will be replied within 12 hours.
(2)Dedication to quality, supply & service.
(3)Strictly on selecting raw materials.
(4)Reasonable & competitive price, fast lead time.
Our company is based on the optical valley biological city,making full use of the park policy advantages, focusing on the research and development of biological medicine.
The pharmaceutical intermediates are mainly applied to anti-cancer, anti-depression, cardiovascular, diabetes and other new medicine. The chemical intermediates mainly refer to heterocyclics and OLED intermediates.Our factory produce new fine chemical materials which are mainly used in water treatment, bactericidal and anti-corrosion, dyes, electronic materials and other industry fields.
Wuhan Kanal has export & import license, and hazard chemical sales license. The products are exported to America, Brazil, South Korea, Japan, Taiwan, Malaysia, Thailand, Indonesia, Europe union and other countries or regions.
Under rich experiences and excellent international reputation, the company becomes a quite influential enterprise in China's API field. Wuhan Kanal sincerely look forward to establishing long good cooperation with our customers from all over the world.
CAS NO:118072-93-8
CAS NO:51-42-3
CAS NO:138071-82-6
CAS NO:199739-10-1
CAS NO:69815-49-2
CAS NO:1420477-60-6
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View